Novo Nordisk A/S (NYSE:NVO) Stock Price Down 0.2%

Novo Nordisk A/S (NYSE:NVO)’s share price dropped 0.2% during trading on Thursday . The company traded as low as $124.13 and last traded at $124.69. Approximately 940,029 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 4,989,729 shares. The stock had previously closed at $124.93.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of recent research reports. UBS Group initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday, April 1st. BMO Capital Markets started coverage on Novo Nordisk A/S in a report on Friday. They issued an “outperform” rating and a $163.00 target price for the company. Finally, Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Trading Down 0.7 %

The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The stock has a 50-day simple moving average of $125.93 and a two-hundred day simple moving average of $109.61. The firm has a market capitalization of $558.79 billion, a P/E ratio of 46.03, a price-to-earnings-growth ratio of 2.09 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.33 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were given a $0.664 dividend. This represents a dividend yield of 0.9%. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s payout ratio is presently 49.17%.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. IHT Wealth Management LLC grew its stake in Novo Nordisk A/S by 3.5% during the 4th quarter. IHT Wealth Management LLC now owns 2,369 shares of the company’s stock worth $321,000 after buying an additional 80 shares during the last quarter. Cravens & Co Advisors LLC grew its stake in Novo Nordisk A/S by 1.0% during the 1st quarter. Cravens & Co Advisors LLC now owns 8,250 shares of the company’s stock worth $1,059,000 after buying an additional 85 shares during the last quarter. U.S. Capital Wealth Advisors LLC grew its stake in Novo Nordisk A/S by 0.6% during the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock worth $1,595,000 after buying an additional 90 shares during the last quarter. Hancock Whitney Corp grew its stake in Novo Nordisk A/S by 4.1% during the 1st quarter. Hancock Whitney Corp now owns 2,342 shares of the company’s stock worth $373,000 after buying an additional 92 shares during the last quarter. Finally, Clarius Group LLC grew its stake in Novo Nordisk A/S by 0.5% during the 4th quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock worth $1,914,000 after buying an additional 93 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.